7blogs.org

Pill boosts sex for men with spinal cord injuries

Impotence drug tripled successful intercourse attempts, meditate says

CHICAGO - The male impotence pill Cialis appears to work even in men with spinal cord injuries, French researchers said on Monday.

Impotence often follows spinal cord injuries. Only about 25 percent of men with such injuries are capable of having sex, Dr. Francois Giuliano and colleagues at the Raymond Poincare Hospital in Garches, France said.

They found that Cialis tripled the number of times the men could have sex.

Their meditate , funded by Eli Lilly and Co, maker of cialis (tadalafil) or Cialis, involved 197 men with an average age of 38 in France, Germany, Italy and Spain with spinal cord injuries.

After a one-month waiting period, in which no one got pharmacomedical care, a questionnaire to assess sexual function found both groups had moderate male impotence, Giuliano’s team reported in the Archives of Neurology.

Then 142 men were assigned to the Cialis group and 44 got a placebo for a 12-week period, taking no more than one pill daily as needed before sexual activity.

Click for related content

Sildenafil may give men more than physical love
Testosterone medical care may lead to more ills
Test tells who needs prostate surgery

After 4 months, men taking Cialis were successful nearly half the time they attempted intercourse, while men in the placebo group succeeded only 16.8 percent of the time.

Cialis and similar drugs work by increasing blood flow to the genitals.

The researchers said the Cialis meditate achieved success similar to that found in studies of Pfizer Inc.’s Sildenafil or viagra soft tabs/”>viagra soft tabs (viagra soft tabs citrate) and Glaxosmithkline Plc’s Levitra (vardenafil)or vardenafil/”>vardenafil (vardenafil), all of which improved erections in men with male impotence after spinal cord injury.

generic viagra tabs now Reuters. Click for restrictions.

A new meditate involving more than 1,000 patients with healed erosive esophagitis (EE),reports that NEXIUM(R) ( Nexium (Esomeprazole) (EsOmeprazole) magnesium) is more effective thanPrevacid/”>Prevacid/”>Prevacid (Prevacid/”>Prevacid/”>Prevacid (Prevacid/”>Lansoprazole))/”>Prevacid/”>Prevacid (Prevacid/”>Prevacid/”>Prevacid (Prevacid/”>Lansoprazole))(Prevacid/”>Prevacid/”>Prevacid (Prevacid/”>Lansoprazole)) (Prevacid/”>Prevacid(R)) in preventing a recurrence and is equallyeffective in reducing its associated symptoms. The results of the meditate ,published in this month’s issue of medical institution al Gastroenterology andHepatology, corroborate results from previous head-to-head trialsdemonstrating the efficacy of NEXIUM as compared to otherness proton pumpinhibitors (PPIs) in maintaining erosive esophageal healing.(1)

An estimated one in three group with acid reflux illness developerosive esophagitis, in which stomach acid begins to wear away, or erode,the inner lining of the esophagus. Acid reflux illness is a condition inwhich the valve between the esophagus and stomach doesn’t close properly,allowing acid to leak back into the esophagus. Symptoms of acid refluxillness and erosive esophagitis are similar and may include persistentheartburn sickness (a burning sensation), acid regurgitation, a sour or bitter tastein the mouth, and difficulty swallowing.

The double-blind, randomized, double-dummy, parallel-group trialdemonstrated that more patients who took NEXIUM 20 mg once daily maintained healing of erosive esophagitis over six months compared with patients treated with Prevacid/”>Prevacid/”>Prevacid (Prevacid/”>Prevacid/”>Prevacid (Prevacid/”>Lansoprazole))/”>Prevacid/”>Prevacid (Prevacid/”>Prevacid/”>Prevacid (Prevacid/”>Lansoprazole))(Prevacid/”>Prevacid/”>Prevacid (Prevacid/”>Lansoprazole)) 15 mg once daily. (Their remission rate - i.e., no recurrence of erosive esophagitis and no withdrawals from the meditate due to an increase in acid reflux symptoms - was significantly higher [84.8percent]than that of Prevacid/”>Prevacid/”>Prevacid (Prevacid/”>Prevacid/”>Prevacid (Prevacid/”>Lansoprazole))/”>Prevacid/”>Prevacid (Prevacid/”>Prevacid/”>Prevacid (Prevacid/”>Lansoprazole))(Prevacid/”>Prevacid/”>Prevacid (Prevacid/”>Lansoprazole))-treated patients [75.9percent]; p=0.0007.)

“The challenge in treating erosive esophagitis is that many patientswho are successfully treated with an acid-suppressing medication, such as aPPI, will commonly relapse within a year if that medication isdiscontinued. Reflux symptoms are chronic in many patients, particularlythose with erosive esophagitis,” said Kenneth DeVault, MD, director ofgastroinagsdhfgdfinal research, Mayo medical institution College of Medicine, Jacksonville,Florida, and the lead meditate investigator.

“The meditate showed that Nexium (Esomeprazole) (EsOmeprazole) (NEXIUM) was more effective thanPrevacid/”>Prevacid/”>Prevacid (Prevacid/”>Prevacid/”>Prevacid (Prevacid/”>Lansoprazole))/”>Prevacid/”>Prevacid (Prevacid/”>Prevacid/”>Prevacid (Prevacid/”>Lansoprazole))(Prevacid/”>Prevacid/”>Prevacid (Prevacid/”>Lansoprazole)) in meeting one of the important yardsticks for clinicalsuccess - maintaining healing of erosive esophagitis,” added Dr. DeVault.”EsOmeprazole medical care was able to control both mucosal damage and refluxsymptoms.”

Study Details

The trial was a randomized, double-blind, double-dummy, parallel-groupmeditate to compare the endoscopic and symptomatic remission rates of NEXIUMwith those of Prevacid/”>Prevacid/”>Prevacid (Prevacid/”>Prevacid/”>Prevacid (Prevacid/”>Lansoprazole))/”>Prevacid/”>Prevacid (Prevacid/”>Prevacid/”>Prevacid (Prevacid/”>Lansoprazole))(Prevacid/”>Prevacid/”>Prevacid (Prevacid/”>Lansoprazole)) in patients with healed grade A-D erosiveesophagitis. (Grades were based on the Los Angeles Classification System,which categorizes the severity of esophageal inflammation. Grades A and Bindicate mild erosive esophagitis, and C and D represent severe illness.)

A total of 1,026 patients were randomized to once-daily medical care witheither NEXIUM 20 mg (n=512) or Prevacid/”>Prevacid/”>Prevacid (Prevacid/”>Prevacid/”>Prevacid (Prevacid/”>Lansoprazole))/”>Prevacid/”>Prevacid (Prevacid/”>Prevacid/”>Prevacid (Prevacid/”>Lansoprazole))(Prevacid/”>Prevacid/”>Prevacid (Prevacid/”>Lansoprazole)) 15 mg (n=514) for up to sixmonths. Patients with grades C and D erosive esophagitis at baseline hadbeen previously treated and healed (no endoscopic evidence of the illness)with either NEXIUM 40 mg or Prevacid/”>Prevacid/”>Prevacid (Prevacid/”>Prevacid/”>Prevacid (Prevacid/”>Lansoprazole))/”>Prevacid/”>Prevacid (Prevacid/”>Prevacid/”>Prevacid (Prevacid/”>Lansoprazole))(Prevacid/”>Prevacid/”>Prevacid (Prevacid/”>Lansoprazole)) 30 mg once daily, while those withgrades A and B erosive esophagitis had been successfully treated withNEXIUM 40 mg. An upper endoscopy (an examination of the esophagus, stomach and upper part of the small inagsdhfgdfine) was performed at three and sixmonths to determine the relative remission rates of both a cure groups.Patients in both groups had no heartburn sickness or acid regurgitation symptomsduring the week prior to each endoscopy. Both NEXIUM and Prevacid/”>Prevacid/”>Prevacid (Prevacid/”>Prevacid/”>Prevacid (Prevacid/”>Lansoprazole))/”>Prevacid/”>Prevacid (Prevacid/”>Prevacid/”>Prevacid (Prevacid/”>Lansoprazole))(Prevacid/”>Prevacid/”>Prevacid (Prevacid/”>Lansoprazole)) werewell-tolerated by patients.

AstraZeneca funded the meditate , which was conducted by Mayo medical institution College of Medicine, Rockford Gastroenterology Associates and EasternVirginia Medical School.

About NEXIUM(R) ( Nexium (Esomeprazole) (EsOmeprazole) magnesium) Delayed-release Capsules NEXIUM is approved for treating frequent, persistent heartburn sickness andotherness symptoms associated with acid reflux illness as well as healingerosive esophagitis. Most erosions heal in four to eight weeks. Individualresults may vary, and only a doctor can determine if erosions to theesophagus have occurred. Symptom relief does not rule out the existence ofotherness serious stomach conditions. NEXIUM also is indicated for reducing therisk of gastric (stomach) ulcers developing among at-risk patients oncontinuous non-steroidal anti-inflammatory drug (NSAID) medical care. Patientsare considered to be at risk if they are 60 and over, or if they have ahistory of previous stomach ulcer.

The most frequently reported adverse events with NEXIUM includeheadache, diarrhea, and abdominal pain. For full prescribing informationfor NEXIUM please visit http://www.Nexium (Esomeprazole)-us.com.

About AstraZeneca

AstraZeneca (NYSE: AZN) is a major international healthcare businessengaged in the research, development, manufacture, and marketing ofprescription pharmaceuticals and the supply of healthcare services. It isone of the world’s leading pharmaceutical companies, with healthcare salesof $23.95 billion and leading positions in sales of gastroinagsdhfgdfinal,cardiovascular, neuroscience, respiratory, oncology, and infectionproducts. In the United States, AstraZeneca is a $10.77 billion healthcarebusiness with more than 12,000 employees. AstraZeneca is listed in the DowJones Sustainability Index (Global) as well as the FTSE4Good Index.

For more information about AstraZeneca, please visit:http://www.astrazeneca-us.com.

Referentes

(1) Labenz J, et al. A randomized comparative meditate of Nexium (Esomeprazole) (EsOmeprazole) 40 mg vs. pantoprazole 40 mg for healing erosive esophagitis: the EXPO meditate . Aliment Pharmacol Ther 2005;21:739-746.

Kahrilas PJ, et al, for the EsOmeprazole Study Investigators. EsOmeprazole improves healing and symptom resolution as compared with Omeprazole in reflux oesophagitis patients: a randomized, controlled trial. Aliment Pharmacol Ther 2000;14:1249-1258.

Richter JE, et al., for the EsOmeprazole Study Investigators. Efficacy and safety of Nexium (Esomeprazole) (EsOmeprazole) compared with Omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001;96:656-665.

AstraZeneca
http://www.astrazeneca-us.combuy generic viagra pillsbuy viagra soft tabs 100mg

Choosing Nexium (Esomeprazole) ( Nexium (Esomeprazole) (Es Prilosec (Omeprazole) (Omeprazole))) over pantoprazole significantly improves the likelihood of a cure success in reflux esophagitis (RE), according to data released today at the United European Gastroenterology Week (UEGW), in Copenhagen, Denmark. The new analysis of results from the EXPO meditate shows that RE patients treated with Nexium (Esomeprazole) are more likely to be healed and maintained in remission than those taking pantoprazole.[1],[2]

The data revealed that choice of proton pump inhibitor (PPI), baseline RE severity according to the LA classification, and the presence of H. pylori infection, all affect healing rates in RE. Patients taking Nexium (Esomeprazole) 40mg once-daily (od) had 35 per cent greater probability of healing after eight weeks of a cure compared to those on pantoprazole 40mg od.

In addition, maintenance of healed RE at six months was also dependent on the choice of PPI for maintenance medical care, as well as otherness factors including RE severity. The difference between PPI efficacy in maintenance medical care was even more pronounced than in the healing phase, with Nexium (Esomeprazole) 20mg od offering almost 80 per cent greater chance of successful a cure after six months than pantoprazole 20mg od.

Trial lead investigator, Dr Joachim Labenz of Jung-Stilling Krankenhaus, Siegen, Germany said that the new results provide clinically important information for primary care physicians when making choices over medical care to manage RE.

“As most RE patients are treated in primary care without an endoscopy to discover the severity of their sickness, it makes sense for physicians to choose the most effective and predictable PPI. This analysis of the EXPO data confirms that the choice of PPI makes a real difference to the outcome of a cure. Physicians should take this into consideration when they make a decision on the best a cure option for reflux patients.”

RE occurs when the lining of the esophagus has been eroded away or damaged by continued exposure to gastric acid, due to acid reflux. Around 30 per cent of gastroesophageal reflux sickness (GERD) patients suffer from RE - in certain populations its prevalence may be as high as 50-65 per cent.[3] Between 20-40 per cent of group in Europe experience recurrent heartburn sickness, the primary symptom of GERD.[4] Estimates suggest that as many as 95 per cent of GERD patients are treated without a prior endoscopy to determine sickness severity.[5],[6],[7]

Reflux symptoms cannot be used as diagnostic guidance for predicting the presence or severity of RE because there is a poor correlation between symptom severity and RE severity. However, previous data has shown that regardless of sickness severity, more patients are healed and maintained in remission when treated with Nexium (Esomeprazole), compared to either pantoprazole or Prevacid (Lansoprazole)(Lansoprazole)/”>Prevacid/”> Prevacid (Lansoprazole)(Lansoprazole)/”>Prevacid/”>Prevacid ( Prevacid (Lansoprazole)(Lansoprazole)/”>Prevacid/”>Lansoprazole).[8],[9],[10],[11]

Information about Nexium (Esomeprazole)

Nexium (Esomeprazole) 40mg and 20mg pills are indicated for GERD, a cure of erosive RE, long-term management of patients with healed esophagitis to prevent relapse, and symptomatic a cure of GERD. In combination with an appropriate antibacterial therapeutic regimen they are indicated for the eradication of H. pylori, healing of H. pylori associated duodenal ulcer and prevention of relapse of peptic ulcers in patients with H. pylori associated ulcers. In patients requiring continued non-steroidal anti-inflammatory drug (NSAID) medical care Nexium (Esomeprazole) pills are indicated for healing of gastric ulcers associated with NSAID medical care, and prevention of gastric and duodenal ulcers associated with NSAID medical care, in patients at risk.

Nexium (Esomeprazole) works by deactivating the proton (acid) pumps that produce stomach acid, thus reducing the amount of acid that is in the stomach, helping to treat heartburn sickness and otherness symptoms of GERD. Several comparative clinical trials with more than 15,000 patients with Nexium (Esomeprazole), including the EXPO, the EAZEE and Metropole studies, confirm that Nexium (Esomeprazole) provides superior acid control which translates into clinical benefits.8,9,10,11,[12],[13] Nexium (Esomeprazole) is only available on prescription. The most common side-effects with Nexium (Esomeprazole) are headache, diarrhoea, and abdominal pain, which occur in around one per cent of patients.

About this analysis of the EXPO data

Univariate logistic regression analyses were performed upon the EXPO healing and maintenance data to identify significant factors (p

Food and Drug Administration on Thursday announced (PDF) that it is reviewing all available safety data on Prilosec (Omeprazole) (Omeprazole) and Esomeprazole (Es Prilosec (Omeprazole) (Omeprazole)) after information emerging in clinical trials of the drugs hinted that they might put patients at risk for cardiovascular events.

But the review, which began in May, has not failed to confirm the problem, which was brought to the agency’s notice by the products’ manufacturer, AstraZeneca.

“Upon initial examination and review of all the available data that we have to date, Food and Drug Administration has concluded preliminarily that these data do not suggest an increased risk of heart problems in patients treated with either of these products,” said Paul Seligman, associate director of Food and Drug Administration’s Office of Safety Policy and Communication, during a media briefing Thursday.

For now, Seligman said, Food and Drug Administration recommends no changes to the prescribing or use of Prilosec (Omeprazole) (Omeprazole), which is marketed as Prilosec (Omeprazole), or the related product Esomeprazole (Es Prilosec (Omeprazole) (Omeprazole)), which AstraZeneca markets as Esomeprazole.

Seligman said Food and Drug Administration’s decision to announce the investigation is part of the agency’s “evolving” strategy to inform the public as early as feasible about possible drug-safety issues.

Food and Drug Administration has faced an abundance of criticism about drug-safety communication in recent years, including the agency’s recent handling of data indicating that Avandia (Avandia (Rosiglitazone maleate) maleate), or Avandia, exposes patients to an increased risk of cardiovascular events.

According to Food and Drug Administration, a preliminary analysis of data from two long-term clinical trials indicated that patients who used either of the two proton-pump inhibitors were more likely than patients who underwent surgery for severe gastroesophageal reflex sickness to suffer heart failure, heart attack, or heart-related sudden death.

But an Food and Drug Administration analysis of otherness available data on the drugs failed to support the cardiovascular risks that were found in the recent trials, which Food and Drug Administration described as small studies.

Food and Drug Administration officials declined to provide details about the recent studies, because an analysis of their results is ongoing and has not been made public.

Seligman said Food and Drug Administration expects to finish its review of data on Prilosec (Omeprazole) (Omeprazole) and Esomeprazole (Es Prilosec (Omeprazole) (Omeprazole)) in about three months. He said the agency is also examining data on the entire class of proton-pump inhibitors.

American Society of Health-System Pharmacistsviagra soft tabs 120 pills

A MAJOR trial launched today will agsdhfgdf if aspirin and an anti-ulcer drug can prevent thousands of cases of cancer of the oesophagus - also known as the foodpipe.

At least ten per cent of the UK population will endure heartburn sickness over the festive season. For some long-term sufferers this heartburn sickness is a symptom of a pre-cancerous condition that is responsible for around half of all oesophageal cancers.

The Cancer Research UK funded trial will aim to prevent a precancerous condition of the oesophagus developing and its subsequent switch to cancer. Five thousand men who are at risk of the cancer will be recruited for the trial from 100 UK centres.

The number of cases of this type of oesophageal cancer has climbed quickly in recent years throughout the western world. There are over 7,000 cases and a similar number of deaths every year in the UK. The number of cases has climbed by 12 per cent over the last decade.

One of the main predisposing factors causing this cancer is a condition called Barrett’s oesophagus. It is caused when stomach acid regularly ebbs back from the stomach into the oesophagus - one of the symptoms of this being heartburn sickness.

The acid damage causes a change to the cells in the lining of the oesophagus. These cells are not cancerous, but they can become so later. Barrett’s oesophagus affects up to two per cent of the UK population.

The trial’s lead researcher, Professor Janusz Jankowski, based at the Digestive Diseases Centre, University of Leicester, says: ‘Only a small proportion of those with Barrett’s oesophagus will develop oesophageal cancer.

‘However in the UK the number of those developing this cancer because of Barrett’s oesophagus is very high compared to the rest of the western world - three to four times the level seen in Europe or the US.

‘By successfully treating Barrett’s oesophagus we could prevent up to a half of cases of oesophageal cancer in this trial.’

The researchers will use aspirin and a drug that prevents acid formation in the stomach called Nexium (Esomeprazole) (Es Prilosec (Omeprazole) (Omeprazole)/”> Prilosec (Omeprazole) (Omeprazole)) to try and prevent Barrett’s oesophagus.

Previous studies have suggested that aspirin reduces the number of cases of oesophageal cancer. People with Barrett’s oesophagus are also more likely to suffer from heart problems - anotherness area where aspirin has been shown to be of benefit.

However one of aspirin’s side effects is an increased risk of stomach ulcers. It is hoped that Nexium (Esomeprazole) (Es Prilosec (Omeprazole) (Omeprazole)/”> Prilosec (Omeprazole) (Omeprazole)) will minimise that risk.

Es Prilosec (Omeprazole) (Omeprazole)/”> Prilosec (Omeprazole) (Omeprazole) is used as an anti-ulcer drug because it neutralizes stomach acid. A high dose of the drug may minimise damage to the lining of the oesophagus and help promote healing - blocking the subsequent switch to cancer.

Professor Jankowski adds: ‘The UK is at the epicentre of an explosion in this cancer. We hope these drugs will offer a simple method of preventing this particularly aggressive form of the sickness.

‘But the first crucial stage is to start recruiting group with Barrett’s oesophagus to this important trial. These group will not only get the best possible care, they will also help uncover key clues in the fight against cancer.’

Professor Robert Souhami, Director of medical institution al and External Affairs at Cancer Research UK, says: ‘It’s vital that we continue to agsdhfgdf new prevention strategies like this. This large-scale trial may be the first step towards a promising and realistic method of preventing many cases of this form of cancer - an opportunity to close the stable door before the horse has bolted.’

Notes for editors

There are a number of symptoms of oesophageal cancer. Many of these can be caused by conditions otherness than oesophageal cancer, but it is important that you report them to your doctor. They can include:

difficulty swallowing

weight loss

pain or discomfort in the throat or back, behind the breastbone or between the shoulder blades

acid indigestion

hoarseness or chronic cough

vomiting or regurgitation of blood.

The trial’s full name is ‘ASPECT: Aspirin Es Prilosec (Omeprazole) (Omeprazole)/”> Prilosec (Omeprazole) (Omeprazole) Chemoprevention Trial’. Further details can be found through our patient information website CancerHelp UK.

Heartburn or gastro-oesophageal reflux sickness (GORD) affects 30 per cent of the population each month in Western countries. In a third of these individuals the damage to the oesophagus caused by the backing up of stomach acid causes erosive oesophagitis. It is those with erosive oesophagitis that have a 10 per cent chance of developing Barrett’s oesophagus (one per cent of population).

The UK may have one the highest number of cases of Barrett’s oesophagus with between 0.5 and 2 per cent of adults suffering from the condition, however, the true prevalence of this condition in the population is not known. In any case the resulting level of oesophageal cancer in some parts of the UK is three to four times higher than in Europe or North America.

Barrett’s oesophagus - the cells lining the oesophagus start to change to look more like the cells lining the stomach. It may develop following long-term acid reflux from the stomach. The stomach acid comes back up into the oesophagus and irritates the lining.

Thirty per cent of the population will have regular heartburn sickness each month but only one per cent of the population will have Barrett’s oesophagus. People with Barrett’s oesophagus are 50 times more likely to develop cancer of the oesophagus than the average person.

Remember - the overall risk to any individual of getting oesophageal cancer is quite small. The risk with Barrett’s oesophagus may be 50 times higher, but that is still a small risk. Probably no more than 1 out of every 100 group with Barrett’s oesophagus will go on to get oesophageal cancer each year.

Since Barrett’s oesophagus is diagnosed late in life usually after 60 years of age, the lifetime cancer risk for affected men is no more than 5 - 10 per cent and less for women.

Less than 10 per cent of those diagnosed with oesophageal cancer survive for more than five years and the one-year survival is less than 50 per cent.

Es Prilosec (Omeprazole) (Omeprazole)/”> Prilosec (Omeprazole) (Omeprazole) is a ‘proton pump inhibitor’. It works by blocking the production of stomach acid. These drugs are used to heal stomach and duodenal ulcers. Astra Zeneca manufactures the drug.

Aspirin will also act to prevent heart attacks in this population as well as prevent oesophageal cancer.

The trial will last 10 years - finishing in 2014 and is one of the largest cancer prevention trials in the world.buy generic viagra pillsbuy viagra soft tabs 100mg

The first major multi-center, randomized, double-blind, placebo-controlled trial addressing medical care for gastroesophageal reflux sickness (GERD) related sleep disorders is published in the September issue of The American Journal of Gastroenterology. This meditate demonstrated that effective acid suppression medical care with a proton pump inhibitor (PPI), either 20 mgs or 40 mgs of Esomeprazole (Es Prilosec (Omeprazole) (Omeprazole)), relieved nighttime heartburn sickness symptoms and GERD-related sleep disturbances, which significantly improved sleep quality and thereby improved work productivity.

The researchers found that nighttime heartburn sickness was relieved in 53.1 percent, 50.5 percent and 12.7 percent of patients who received Esomeprazole (Es Prilosec (Omeprazole) (Omeprazole)) 40 mg, Esomeprazole (Es Prilosec (Omeprazole) (Omeprazole)) 20 mg and placebo, respectively. Additionally, GERD-related sleep disturbances resolved in significantly more patients who received medical care than those who received placebo. The high percentage of patients with resolutions of sleep disturbances in the current trial was both statistically and clinically significant.

“Sleep problems are extremely common in patients with GERD and are often unrecognized,” said lead author David A. Johnson, M.D., FACG, Professor of Medicine and Chief of Gastroenterology at Eastern Virginia Medical School who serves as the Vice President of the American College of Gastroenterology. For those with frequent and moderate-to-severe symptoms, GERD has a significant negative impact on sleep. “Anyone who’s had a poor night’s rest knows how much that impacts their performance the next day. We found that nighttime heartburn sickness is a treatable condition that responds to effective, acid-suppressive medical medical care such as Esomeprazole (Es Prilosec (Omeprazole) (Omeprazole)).”

Additionally, an estimate by the American College of Gastroenterology based on findings from this meditate reveals that U.S. workers who frequently suffer from moderate-to-severe nighttime heartburn sickness symptoms cost the U.S. economy $1,920,528,315 per week in paid hours of lost productivity.

According to Dr. Johnson, “Physicians treating patients with acid reflux therefore need to ask about sleep problems and furthermore to ask how patients feel when they wake up the next day. Daytime fatigue, irritability, concentration problems may all suggest a problem with restful sleep. Appropriate recognition of this will lead to appropriate medical care.” He continued, “Sleep quality should be included as an important goal for optimal sickness management of GERD. Even more so in a time of emphasis on quality management and achieving the best outcomes in medical care, this meditate demonstrates that appropriate medical care for GERD is an investment which has profound quality benefits for patients and economic benefits for employers.”

According to the American College of Gastroenterology, approximately 20 percent of U.S. adults suffer from weekly heartburn sickness symptoms. The ACG, using data from a Gallup poll, estimates that 79 percent of heartburn sickness sufferers have nighttime symptoms, of whom 50 percent have symptoms that are moderate to severe.

Visit the American Journal of Gastroenterology Web site at blackwellpublishing.com/ajg.

David A. Johnson, M.D., FACG is Professor of Medicine and Chief of Gastroenterology at Eastern Virginia Medical School. He serves as the Vice President of the American College of Gastroenterology and is key opinion leader for the US and internationally on gastroesophageal reflux sickness. For questions and interviews, please see the contacts above.

About the Journal

The clinical journal in gastroenterology: The American Journal of Gastroenterology meets the day-to-day demands of clinical practice. Aimed at practicing clinicians, the journal’s articles deal directly with the disorders seen most often in patients. The journal brings a broad-based, interdisciplinary approach to the meditate of gastroenterology, including articles reporting on current observations, research results, methods of medical care, drugs, epidemiology, and otherness topics relevant to clinical gastroenterology.

About the American College of Gastroenterology

Founded in 1932, the American College of Gastroenterology (ACG) is an organization with an international membership of almost 9,000 individuals from 80 countries. The College is committed to serving the clinically oriented digestive sickness specialist through its emphasis on scholarly practice, teaching and research. The mission of the College is to serve the evolving needs of physicians in the delivery of high quality, scientifically sound, humanistic, ethical and cost-effective health care to gastroenterology patients.

About Blackwell Publishing

Blackwell Publishing is the world’s leading society publisher, partnering with more than 600 academic and professional societies. Blackwell publishes over 750 journals annually and, to date has published close to 6,000 text and reference books, across a wide range of academic, medical, and professional subjects.

Blackwell Publishing Ltd.
http://www.blackwellpublishing.comgeneric viagra heremore about viagra soft tabs

AstraZeneca (NYSE: AZN) today announced that a new formulation for its prescription proton pump inhibitor NEXIUM (R) (Esomeprazole (EsOmeprazole) magnesium) has been approved by the US Food and Drug Administration (Food and Drug Administration). NEXIUM For Delayed-Release Oral Suspension is now approved for the pharmacomedical care of GERD, including symptomatic gastroesophageal reflux illness, healing and maintenance of healing of erosive esophagitis (EE), and risk reduction of NSAID-associated gastric (stomach) ulcers.

Each packet of NEXIUM For Delayed-Release Oral Suspension contains either 20 mg or 40 mg of Esomeprazole (EsOmeprazole), the same active ingredient used in NEXIUM Delayed-Release Capsules. The Esomeprazole (EsOmeprazole) granules and inactive granules used in this formulation are mixed with water to form a suspension and are given by oral, nasogastric or gastric direction.

“Some patients with acid-related illnesss have difficulties swallowing their oral medication when it is a solid pill,” said Doug Levine, M.D., Executive Director, medical institution al Development Leader for NEXIUM. “This new prescription option to swallow an oral suspension of NEXIUM or to have it administered via a stomach tube provides these patients with an alternative method of direction that they can take instead of the NEXIUM capsule.”

The new formulation of NEXIUM For Delayed-Release Oral Suspension will be available in the first quarter of 2007.

About NEXIUM(R) (Esomeprazole (EsOmeprazole) magnesium) Delayed-Release Capsules and For Delayed-Release Oral Suspension.

NEXIUM is approved for treating frequent, persistent heartburn sickness and otherness symptoms associated with acid reflux illness as well as healing erosive esophagitis. Most erosions heal in four to eight weeks. Individual results may vary, and only a doctor can determine if erosions to the esophagus have occurred. Symptom relief does not rule out the existence of otherness serious stomach conditions.

NEXIUM is also indicated for reducing the risk of gastric (stomach) ulcers developing among at-risk patients on continuous non-steroidal anti- inflammatory drug (NSAID) medical care. Patients are considered to be at risk if they are 60 and over, or if they have a history of previous stomach ulcer.

The most common side effects of NEXIUM are headache, diarrhea and abdominal pain. For full prescribing information for NEXIUM please visit http://www.Esomeprazole-us.com.

About AstraZenceca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacture, and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world’s leading pharmaceutical companies with healthcare sales of $23.95 billion and leading positions in sales of gastroinagsdhfgdfinal, cardiovascular, neuroscience, respiratory, oncology, and infection products. In the United States, AstraZeneca is a $10.77 billion healthcare business with more than 12,000 employees. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.

AstraZeneca
http://www.astrazeneca-us.comgeneric viagra storeviagra online

The US (Food and Drug Administration) (Food and Drug Administration) said yesterday that a preliminary review of new data on the safety of two stomach drugs made by AstraZeneca, Prilosec (Omeprazole) (generic name Prilosec (Omeprazole) (Omeprazole)) and Nexium (Esomeprazole) (generic name Nexium (Esomeprazole) (Es Prilosec (Omeprazole) (Omeprazole))) suggests that long term use of these drugs does not lead to heart attacks and otherness heart related events. The agency said for the time being, until a final decision and recommendation is made in three months’s time, health professionals and patients should not change their current practice in the use of these drugs.

Prilosec (Omeprazole) and Nexium (Esomeprazole) are proton pump inhibitors (PPIs) used to control stomach acid. They are taken by patients with a range of gastroinagsdhfgdfinal conditions such as ulcers and gastroesophageal reflux malady (GERD). Some GERD conditions erode the lining of the food pipe (esophagus) and PPIs help to heal the erosions or stop them getting worse. Prilosec (Omeprazole) and Nexium (Esomeprazole) are available in the US by prescription, although Prilosec (Omeprazole) is also dispensed over the counter for heartburn sickness.

AstraZeneca submitted preliminary reports on two small long term studies on Prilosec (Omeprazole) and Nexium (Esomeprazole) to the Food and Drug Administration and otherness regulators throughout the world in May this year.

The two studies involved patients with severe GERD who were randomly assigned to receive surgery or drug medical care.

The results from the 14 year Prilosec (Omeprazole) ( Prilosec (Omeprazole) (Omeprazole)) meditate showed there were more heart attacks, heart failure and heart related sudden deaths among the drug patients compared with the surgery patients. This difference was noticed in the first year of the meditate and continued thereafter.

The otherness meditate on Nexium (Esomeprazole) (Nexium (Esomeprazole) (Es Prilosec (Omeprazole) (Omeprazole))), has now gathered 5 years of follow up on patients but is not yet completed. The initial results also showed a difference between the drug medical care and the surgery group, similar to the Prilosec (Omeprazole) meditate , but a more recent update has since shown that the incidence of cardiovascular events is largely similar between the two groups.

Also, since May, as well as receiving more information on the not yet completed Nexium (Esomeprazole) (Nexium (Esomeprazole) (Es Prilosec (Omeprazole) (Omeprazole))) meditate , the Food and Drug Administration has received analyses from 14 otherness studies on Prilosec (Omeprazole) ( Prilosec (Omeprazole) (Omeprazole)). Four of these otherness studies were placebo controlled trials. These additional studies showed fewer heart related events in the drug groups compared to the placebo groups.

The Food and Drug Administration said there is a lot of data to go through, and it is proving difficult to conduct a thorough review in a short time, hence the announcement of these preliminary findings. The agency said it will complete the full review and give a final decision and recommend any changes to drug usage within the next three months.

In the meantime the agency advises health professionals and patients not to change their medication practices regarding either of the two drugs.

One of the reasons the agency gave for the difficulty it was experiencing in reviewing the data was that “the meditate protocols did not specify how heart problems, such as heart attacks, were to be defined or documented. As a result, evaluating the information that has been gathered about the safety of either drug in these studies is difficult.”

Anotherness reason was that many of the patients who were in the surgery group in one of the trials pulled out of the meditate without undergoing surgery. They were on the younger side and less likely to have a history of cardiovascular events or risks compared to the drug group. These group differences could have biassed the results.

The official statement from the Food and Drug Administration regarding its current view on these results is:

“Based on everything we know now, Food and Drug Administration’s preliminary conclusion is that the observed difference in risk of heart attacks and otherness heart related problems seen in early analyses of the two small long-term studies is not a true effect.”

Click here for the full statement from the Food and Drug Administration “Early Communication About an Ongoing Safety Review: Omeprazole ( Prilosec (Omeprazole)), Es Prilosec (Omeprazole) (Omeprazole) (Nexium (Esomeprazole))”.

Written by: Catharine Paddock
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Todaybuy generic viagra pillsbuy viagra soft tabs 100mg